Back to Journals » Clinical Interventions in Aging » Volume 5

Aripiprazole for late-life schizophrenia

Authors Rado J, Janicak PG

Published 30 August 2010 Volume 2010:5 Pages 253—258

DOI https://doi.org/10.2147/CIA.S9398

Review by Single-blind

Peer reviewer comments 2


Jeffrey Rado, Philip G Janicak

Psychiatric Clinical Research Center, Rush University Medical Center, Chicago, IL, USA

Abstract: Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger ­populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high co-morbidity rates (both psychiatric and ­medical) in the elderly; age-related changes in pharmacokinetics leading to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole.

Keywords: aripiprazole, schizophrenia, elderly, dopamine partial antagonist

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]